Advancements in modern genetic sequencing technologies will be instrumental to more rationally guiding ASM selection and interventions for individuals with discrete genetic variants in sodium or potassium channel function [41], possibly ultimately resulting in a reduction in the percentage of patients with treatment-resistant epilepsy. This evidence concerns the gene KCNA3 and epilepsy.